Adagene Inc logo

Adagene Inc(ADAG)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.71
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ADAG

11/13/2026: ADAG (1-star) is currently NOT-A-BUY. Pass it for now.

Adagene Inc. is a clinical-stage biopharmaceutical stock operating in the biotechnology sector, focusing on AI-driven antibody-based cancer immunotherapies. The company's main strengths lie in its proprietary SAFEbody masking technology and encouraging clinical data for its lead asset, muzastotug. Its primary investment story centers on expanding mid-stage clinical combinations and monetizing global pharmaceutical partnerships. However, key risks include ongoing operating losses, pre-commercial revenue dependency, and the high attrition rates typical of drug development. The stock suits high-risk growth investors willing to monitor upcoming Phase 2 clinical readouts and cash runway developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers high-upside exposure to clinical-stage oncology pipelines and proprietary antibody platforms.
Momentum investorMixed fitTreat Momentum fit as conditional on a positive Upturn signal (Strong Buy / Buy); trading momentum fluctuates around clinical trial readouts.
Value investorWeak fitAdagene generates net losses and lacks commercial earnings, making it unsuitable for traditional value metrics.
Dividend investorWeak fitThe company pays no dividends, focusing entirely on reinvesting capital into clinical research.
Low-risk investorWeak fitHigh clinical development risks and share price volatility present substantial risk profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotechnology stock valuations swing sharply based on clinical trial updates and market sentiment.
Valuation riskMedium / highValuations depend heavily on speculative future pipeline success rather than current earnings.
Competition risk (oncology immunotherapy competition)HighIntense competition from well-funded oncology rivals can threaten commercial viability.
Business qualityMediumWhile the technology platform is scientifically robust, commercial execution remains unproven.
Dividend incomeLow / noneNo dividend distributions are paid to shareholders.
Execution riskHighSuccess relies entirely on positive clinical data delivery and regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 114.82M USD
Price to earnings Ratio -
1Y Target Price 9.91
Price to earnings Ratio -
1Y Target Price 9.91
Volume (30-day avg) 279.8K shares
Beta 0.66
52 Weeks Range 1.50 - 4.85
Updated Date 11/15/2026
52 Weeks Range 1.50 - 4.85
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.37

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -80.32%
Avg. Invested days 16
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ADAG receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ADAG has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+47.3%) and strong revenue growth (+7332.8%) are partially offset by weak cash generation (FCF margin -204.3%), weak profitability (net margin -229.6%).

Financial Health Rating

★★★★★
ADAG's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 66.7%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is ADAG's strongest growth driver at +7332.8% FY2025 versus FY2024 (strong, 5 stars). Earnings growth (+47.3%, strong) and free-cash-flow growth (+47.3%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 34.5% and approximately 66.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 11.43% supports management-shareholder alignment.

Top 5 Institutional Investors

Jupiter Topco LLC 9.93%
Siren, L.L.C. 3.97%
Deerfield Management Co 3.97%
Ameriprise Financial Inc 2.56%
HSG Holding Ltd 2.00%

Unit Economics (Per $1K Revenue)

★★★★★
ADAG generates approximately $1,000 of gross profit, $-2,795 of operating income, and $-2,043 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 1.66%

Quantitative Style Profile

★★★★★
ADAG has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Collaboration and Licensing AgreementsUpfront licensing fees, research funding, and milestone payments from global pharma partners like Sanofi and Exelixis.Revenue comes primarily from big pharma partnerships validating and funding its technology platforms rather than commercial product sales.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value -7.34M
Price to Sales(TTM) 12.36
Enterprise Value -7.34M
Price to Sales(TTM) 12.36
Enterprise Value to Revenue 1.31
Enterprise Value to EBITDA 1.12
Shares Outstanding 67.14M
Shares Floating 44.83M
Shares Outstanding 67.14M
Shares Floating 44.83M
Percent Insiders 11.43
Percent Institutions 34.51

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.